Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC reported 21 US-listed holdings worth $1.68 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Kailera Therapeutics Inc. (29.6%), Heartflow Inc. (14.7%) and Newamsterdam Pharma Company (7.7%). Against the quarter before, it opened 2 positions, added to 2, trimmed 7 and sold out of 1.
Reported holdings$1.68B+51.7% on Q1 2026
Positions21+1 on Q1 2026
The largest ten87.9%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedAdded toHeldTrimmed
The 14 largest of its 21 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 2Added 2Held 10Trimmed 7Sold out 1
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 2
- Kailera Therapeutics Inc. KLRA$497.5 million
- Hemab Therapeutics Hldgs Inc. COAG$60.6 million
Added to 2
- Alkermes plc. ALKS+1.3 million shares · +218%
- Cabaletta Bio Inc. CABA+7.6 million shares · +78%
Trimmed 7
- Newamsterdam Pharma Company NAMS-3.5 million shares · -48%
- Heartflow Inc. HTFL-2.0 million shares · -19%
- Olema Pharmaceuticals Inc. OLMA-387,989 shares · -5%
- Annexon Inc. ANNX-774,943 shares · -15%
- Kyverna Therapeutics Inc. KYTX-225,000 shares · -7%
- Upstream Bio Inc. UPB-266,262 shares · -31%
- Atea Pharmaceuticals Inc. AVIR-284,999 shares · -12%
Sold out of 1
- Centessa Pharmaceuticals PLC CNTA$25.2 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Kailera Therapeutics Inc. KLRA | 22,583,268 | $497.5 million | 29.58% | new |
| Heartflow Inc. HTFL | 8,448,158 | $247.9 million | 14.74% | -2,000,000 |
| Newamsterdam Pharma Company NAMS | 3,806,566 | $129.0 million | 7.67% | -3,500,000 |
| Savara Inc. SVRA | 17,600,621 | $108.4 million | 6.45% | no change |
| Alkermes plc. ALKS | 1,937,938 | $101.5 million | 6.04% | +1,327,938 |
| Solid Biosciences Inc. SLDB | 9,808,819 | $98.0 million | 5.83% | no change |
| Pharvaris N V PHVS | 2,675,509 | $92.5 million | 5.50% | no change |
| Olema Pharmaceuticals Inc. OLMA | 7,085,249 | $88.6 million | 5.27% | -387,989 |
| Hemab Therapeutics Hldgs Inc. COAG | 1,650,000 | $60.6 million | 3.60% | new |
| Cabaletta Bio Inc. CABA | 17,241,445 | $53.6 million | 3.19% | +7,564,320 |
| X4 Pharmaceuticals Inc. XFOR | 7,967,454 | $37.2 million | 2.21% | no change |
| Dianthus Therapeutics Inc. DNTH | 362,470 | $35.3 million | 2.10% | no change |
| C4 Therapeutics Inc. CCCC | 7,171,910 | $33.5 million | 1.99% | no change |
| Kyverna Therapeutics Inc. KYTX | 2,885,000 | $25.7 million | 1.53% | -225,000 |
| Annexon Inc. ANNX | 4,437,731 | $25.3 million | 1.51% | -774,943 |
| Rapid Micro Biosystems Class A Ord RPID | 8,434,560 | $14.6 million | 0.87% | no change |
| Disc Medicine Inc. IRON | 141,234 | $10.3 million | 0.61% | no change |
| Atea Pharmaceuticals Inc. AVIR | 2,075,639 | $9.7 million | 0.57% | -284,999 |
| Xilio Therapeutics Inc. XLO | 664,021 | $6.4 million | 0.38% | no change |
| Upstream Bio Inc. UPB | 600,949 | $4.2 million | 0.25% | -266,262 |
| Newamsterdam Pharma Company | 99,999 | $2.1 million | 0.13% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.